AAPP has issued a statement opposing the Substance Abuse and Mental Health Services Administration’s (SAMHSA) policy change to prohibit the use of federal funds for the purchase of “fentanyl test strips or any other substance test kits, including xylazine and medetomidine test strips, intended for use by people using drugs.” Restricting access to this tool risks reversing progress in overdose prevention at a time when synthetic adulterants continue to drive morbidity and mortality. Evidence supports the importance of clinicians, first responders, and individuals having access to test strips as an essential component of overdose prevention interventions. Access AAPP’s Policy Statement “The funding and delivery of harm reduction services” for further information and to support your own advocacy in this area.